Extraction of biomedical compounds from the wood of Pterocarpus macarocarpus Kurz heartwood.
Some wood can be used as traditional Chinese medicine. The medicinal value of wood is associated with its extractives. Pterocarpus macarocarpus Kurz heartwood is a kind of top valuable reddish hardwood in making furniture and handicrafts, but the research about medicine value of this wood is not enough. In order to investigate the high value biomedical compounds in Pterocarpus macarocarpus Kurz heartwood, the woody extractives were obtained by Soxhlet extraction and ultrasonic extraction with benzene-ethanol (1:2, v/v) solvent simultaneously and were analyzed by Gas Chromatography-Mass Spectrometer (GC-MS). Combining with the results of the two extraction methods, 44 compounds can be identified in total. Amony these identified compounds, there were 5 flavonoids, 15 terpenes and 3 steroidal compounds. The representative biomedical compositions were homopterocarpin, medicarpin, (-)-pterocarpin, formononetin, β-eudesmol, stigmasterol, linoleic acid and so on, which indicated that the extractives from Pterocarpus macarocarpus Kurz heartwood have huge potential in biomedicine. This research provides scientific basis for further comprehensive utilization of Pterocarpus macarocarpus Kurz heartwood as Chinese medicine.
Chemical constituents and chemotaxonomic study of Glycyrrhiza pallidiflora maxim
Abstract Phytochemical study of Glycyrrhiza pallidiflora Maxim. gave seventeen compounds, including two sterols (3 and 4), four triterpenes (1, 2, 5, 6), ten flavones (7, 9–17), and one pterocarpan (8). The chemotaxonomic significance of G. pallidiflora was discussed, which indicated the close relationship between G. pallidiflora with other species of Glycyrrhiza. Moreover, pallidiflorin can be served as a fingerprint for G. pallidiflora, macedonic acid and echinatin can be recognized as biomarkers for Glycyrrhiza, while formononetin, afrormosin and calycosin may be typical second metabolites for Papilionoideae.
Botulinum toxin in the management of chronic migraine: clinical evidence and experience
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.